Although there is a presumed drug-drug interaction between itraconazole and nonnucleoside reverse-transcriptase inhibitors, the medical literature lacks such documentation. We describe a drug-drug interaction between itraconazole and efavirenz in a patient with disseminated histoplasmosis and acquired immunodeficiency syndrome (AIDS). The drug combination resulted in persistently elevated urinary Histoplasma antigen levels and subtherapeutic plasma itraconazole concentrations. Changing treatment from efavirenz to a protease inhibitor was accompanied by improvements in the desired urinary Histoplasma antigen level and plasma itraconazole concentration.
and multiple fungal organisms consistent with Histoplasma capsulatum. Treatment with amphotericin B deoxycholate was initiated, with good clinical response. After 14 days of amphotericin B treatment, the patient was discharged from the hospital, receiving itraconazole capsules (200 mg once daily).
Over the following several months, there was continued improvement in the patient's clinical symptoms, pancytopenia, and CD4 cell count (up to 140 cells/mL). The patient's urine Histoplasma antigen level correspondingly decreased initially to 4.28 U but did not decrease further. After 11 year of itraconazole treatment, a 12-h plasma itraconazole concentration was measured, but itraconazole was not detected (!0.05 mg/mL). The patient's itraconazole capsule dosage was increased to 200 mg twice daily. However, the patient's urine Histoplasma antigen level was unchanged, and his plasma itraconazole concentration remained undetectable. In addition, no effect was seen when the itraconazole formulation was changed to solution. It was suspected that a drug-drug interaction between itraconazole and the nonnucleoside reverse-transcriptase inhibitor efavirenz was contributing to the low plasma itraconazole concentration. As a result, the patient's antiretroviral regimen was changed to atazanavir (300 mg once daily), ritonavir (100 mg once daily), and emtricitabine-tenofovir (200 mg/300 mg once daily).
Two months later, the patient's plasma itraconazole concentration increased to 3 mg/mL. Three months after the change in antiretroviral treatment, the patient's urine Histoplasma antigen level decreased to 0.6 U. Table 1 summarizes the response in the urine Histoplasma antigen level and plasma itraconazole concentration after the change in treatment.
Discussion. Although the incidence of histoplasmosis has decreased in patients with AIDS since the advent of HAART, histoplasmosis still causes significant morbidity and mortality in this patient population. More than 95% of HIV-infected patients who have histoplasmosis will develop the disseminated form of the disease [1] .
Itraconazole is an important component of treatment for this opportunistic infection-after induction therapy with amphotericin B and as long-term maintenance therapy for HIVinfected individuals [2] . Although one study demonstrated the safety of discontinuation of maintenance therapy for HIVinfected patients [3] , lifelong secondary prophylaxis is still recommended for HIV-infected patients with a history of Histoplasma infection [4] . As a result, it is quite likely that many HIV-infected patients with histoplasmosis will eventually receive both itraconazole and antiretroviral therapy concurrently at some point. However, there are very few studies in the literature regarding drug-drug interactions between itraconazole and antiretroviral medications. This article describes the first known reported case involving a drug-drug interaction between itraconazole and a nonnucleoside reverse-transcriptase inhibitor. Despite clinical improvement in this patient, there was concern about the persistent elevation of his urine Histoplasma antigen level (4.28 U), even after a year of antifungal therapy with itraconazole. The patient was fortunate, however, that no clinical manifestations of treatment failure or relapse of histoplasmosis were associated with this elevated Histoplasma antigen level. Some experts recommend observing the antigen level until it becomes negative or at least р4 U. Close follow-up to monitor for relapse is advised for patients who have not had a known reversion to a negative antigen test result [2] . Increases of the Histoplasma antigen level of у2 U have been shown to be a strong predictor of relapse [5] .
In this case, we considered that the lower dose of itraconazole (200 mg once daily) and use of the capsule formulation may have resulted in the mildly increased urine Histoplasma antigen level. Consequently, the patient's itraconazole dosage was first increased, with no change in the antigen level, and then changed to the solution formulation, which also had no effect.
Itraconazole is predominantly metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme to hydroxyitraconazole and other metabolites [6] . This enzyme pathway also mediates the metabolism of the nonnucleoside reverse-transcriptase inhibitors, including efavirenz and nevirapine [7] . Studies have shown that, when coadministered, nevirapine induces the metabolism of ketoconazole, leading to reduced ketoconazole bioavailability [8] . We speculated that efavirenz was causing a reduced concentration of itraconazole through CYP3A4 enzyme induction in a similar fashion. As a result, we changed the patient's nonnucleoside reverse-transcriptase inhibitorbased antiretroviral regimen to a protease inhibitor-based regimen.
There are a few reports describing the interaction between protease inhibitors and itraconazole. Crommentuyn et al. [9] described how lopinavir-ritonavir increased the concentration of itraconazole by inhibiting CYP3A4, although no changes in lopinavir-ritonavir concentrations were seen. We surmised that the combination of atazanavir and ritonavir would also produce a similar increase in the itraconazole concentration through inhibition of this hepatic enzyme pathway. The patient's laboratory findings were consistent with this drug-drug interaction, with an increase in his plasma itraconazole concentration from undetectable (!0.05 mg/mL) to 3 mg/mL and a decrease in his Histoplasma antigen level from 4.28 U to 0.6 U. We considered this itraconazole concentration to be sufficient, because Wheat et al. [1] proposed that a therapeutic plasma concentration of itraconazole should be at least 2 mg/mL.
As demonstrated by this case report, caution should be taken when prescribing the combination of efavirenz and itraconazole. Careful monitoring of the patient's clinical status for any signs of relapse should be performed, because lower bioavailability of itraconazole may be experienced by the patient. Close follow-up of plasma itraconazole concentrations and Histoplasma antigen levels should be considered. If concern about the efficacy of itraconazole treatment in combination with efavirenz arises, a change in antiretroviral therapy to a protease inhibitor-based regimen is a reasonable option.
